In six adults with a genetic condition causing very high cholesterol, one injection of an experimental gene therapy reduced PCSK9 protein by 74% and LDL cholesterol by 52% after six months, with only mild, temporary side effects.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether YOLT-101 or similar PCSK9-inactivating gene therapies consistently reduce LDL-C and PCSK9 across multiple controlled trials and whether these reductions translate to reduced cardiovascular events.
A systematic review and meta-analysis of all published randomized controlled trials comparing YOLT-101 or similar base-editing therapies to placebo or standard care in adults with heterozygous familial hypercholesterolemia, measuring LDL-C and PCSK9 reduction at 24, 52, and 104 weeks, and reporting major adverse cardiovascular events as the primary endpoint.
Whether YOLT-101 causes a clinically meaningful reduction in LDL-C compared to placebo or standard lipid-lowering therapy in a defined population.
A double-blind, placebo-controlled trial of 200 adults with heterozygous familial hypercholesterolemia, randomized to receive either a single intravenous infusion of YOLT-101 at 0.6 mg/kg or saline placebo, with primary outcomes of LDL-C change at 52 weeks and PCSK9 reduction at 24 weeks, and secondary outcomes including liver enzymes, immune markers, and off-target editing via whole-genome sequencing.
Whether individuals treated with YOLT-101 maintain reduced LDL-C and PCSK9 levels over time and whether they experience fewer cardiovascular events compared to untreated individuals with the same genetic condition.
A prospective cohort study following 500 adults with heterozygous familial hypercholesterolemia who received YOLT-101 and 500 matched controls on standard therapy, tracking LDL-C, PCSK9, liver function, and cardiovascular events annually for 10 years.
Whether YOLT-101 treatment is associated with a lower incidence of myocardial infarction or stroke compared to untreated individuals with the same genetic mutation.
A case-control study comparing 100 individuals with heterozygous familial hypercholesterolemia who experienced a cardiovascular event within 5 years of YOLT-101 treatment to 200 matched controls who did not, assessing prior treatment history, baseline LDL-C, and editing efficiency.
Whether individuals treated with YOLT-101 have lower average LDL-C levels at a single time point compared to untreated individuals with the same condition.
A cross-sectional analysis of 1,000 adults with heterozygous familial hypercholesterolemia, comparing LDL-C and PCSK9 levels between those who received YOLT-101 (at least 6 months prior) and those on standard therapy, adjusting for age, sex, and baseline lipid levels.